Nurix officer files notice to sell $151K in stock

Nurix Therapeutics, Inc. (NRIX) officer Christine Ring has filed a Form 144 to sell 5,787 shares of common stock of Nurix, expected on September 2, 2026, following an exercise of stock options for cash.

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. (NRIX) officer Christine Ring has filed a Form 144 to sell 5,787 shares of common stock of Nurix, expected on September 2, 2026, following an exercise of stock options for cash. The filing also lists multiple prior sales over the past three months, some designated as 10b5-1 plan sales.

Key Figures

Shares to be sold: 5,787 shares Aggregate market value of planned sale: $150,693.48 Past sale on June 25, 2026: 28,935 shares for $580,506.12 +2 more

5 metrics

Shares to be sold 5,787 shares Nurix common stock planned for sale on September 2, 2026 under Form 144

Aggregate market value of planned sale $150,693.48 Market value reported for 5,787 Nurix common shares to be sold

Past sale on June 25, 2026 28,935 shares for $580,506.12 Common stock sale by Christine Ring during the past three months

Past sale on August 3, 2026 (larger tranche) 10,802 shares for $248,991.54 10b5-1 sale of Nurix common stock

Past sale on August 3, 2026 (smaller tranche) 5,787 shares for $133,367.20 10b5-1 sale of Nurix common stock

Key Terms

Rule 144, 10b5-1, Exercise of Stock Options

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 regulatory

"10b5-1 Sales for CHRISTINE RING 1600 Sierra Point Parkway Brisbane CA 94005"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Exercise of Stock Options financial

"Common | 09/02/2026 | Exercise of Stock Options | Issuer"

FAQ

What does Nurix Therapeutics (NRIX) officer Christine Ring plan to sell under this Form 144?

The notice states that 5,787 shares of Nurix common stock are planned to be sold. These shares are tied to an exercise of stock options and are to be sold for cash on or about September 2, 2026.

How are the 5,787 NRIX shares being acquired for the planned sale?

The Form 144 states that the 5,787 shares of Nurix common stock to be sold on September 2, 2026 will come from an Exercise of Stock Options, with the exercise to be paid in cash.

What is the reported market value of the NRIX shares planned for sale?

The filing lists an aggregate market value of $150,693.48 for the 5,787 shares of Nurix common stock to be sold, with the shares listed on NASDAQ as of September 2, 2026.

What recent NRIX stock sales by Christine Ring are disclosed in the past three months?

Disclosed past sales include, for example, 28,935 shares sold on June 25, 2026 for $580,506.12 and 10,802 shares sold on August 3, 2026 for $248,991.54, along with several smaller transactions.

Were any of Christine Ring’s recent NRIX stock sales under a 10b5-1 plan?

Yes. Several entries are labeled “10b5-1 Sales for CHRISTINE RING”, including sales of 5,787 and 10,802 shares on August 3, 2026 and sales of 5,221 and 5,787 shares on July 2, 2026.

Which broker is listed for the planned NRIX share sale?

The broker listed is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, in connection with the planned sale of 5,787 Nurix common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:32 PM Accepted by SEC EDGAR 09/02/2026 - 04:30 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001817199
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	NURIX THERAPEUTICS, INC.
SEC File Number	001-39398
Address of Issuer	1600 Sierra Point Parkway Brisbane CALIFORNIA 94005
Phone	4156605320
Name of Person for Whose Account the Securities are To Be Sold	CHRISTINE RING
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	5787	150693.48	103781683	09/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2026	Exercise of Stock Options	Issuer			5787	09/02/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for CHRISTINE RING 1600 Sierra Point Parkway Brisbane CA 94005	Common	08/03/2026	5787	133367.20
10b5-1 Sales for CHRISTINE RING 1600 Sierra Point Parkway Brisbane CA 94005	Common	08/03/2026	10802	248991.54
CHRISTINE RING 1600 Sierra Point Parkway Brisbane CA 94005	Common	07/30/2026	3847	89953.63
10b5-1 Sales for CHRISTINE RING 1600 Sierra Point Parkway Brisbane CA 94005	Common	07/02/2026	5221	123016.16
10b5-1 Sales for CHRISTINE RING 1600 Sierra Point Parkway Brisbane CA 94005	Common	07/02/2026	5787	136349.82
10b5-1 Sales for CHRISTINE RING 1600 Sierra Point Parkway Brisbane CA 94005	Common	06/25/2026	28935	580506.12

144: Remarks and Signature

Remarks
Date of Notice	09/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/10/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Christine Ring
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)